ArticleBritish journal of pharmacology2005
Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production.
Article in British journal of pharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Proton pump inhibitors and colorectal cancer: A systematic review.World journal of gastroenterology · 2021Pooled it
- Helicobacter pylori infection increases the risk of colorectal adenomas: cross-sectional study and meta-analysis.Digestive diseases and sciences · 2012Pooled it
- N-acetylcysteine nano-spray versus conventional treatment in the management of radiotherapy-induced oral mucositis in oral cancer patients: a randomized clinical trial.BMC oral health · 2026Trial
- In silico discovery of significant pathways in colorectal cancer metastasis using a two-stage optimisation approach.IET systems biology · 2015Trial
- Article
- Increased risk of adenomatous colon polyps in patients with long-term use of proton pump inhibitors: a single-center retrospective study.Journal of Yeungnam medical science · 2025Article
- Effects and mechanisms ofWorld journal of gastroenterology · 2024Review
- Proton Pump Inhibitors Worsen Colorectal Cancer Outcomes in Patients Treated with Bevacizumab.Cancers · 2024Article
- Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study.British journal of cancer · 2021Article
- Gastrin, Cholecystokinin, Signaling, and Biological Activities in Cellular Processes.Frontiers in endocrinology · 2020Review
- Transcriptomics analysis reveals new insights in E171-induced molecular alterations in a mouse model of colon cancer.Scientific reports · 2018Article
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use.Journal of neurogastroenterology and motility · 2018Review
- A retrospective analysis of the role of proton pump inhibitors in colorectal cancer disease survival.Current oncology (Toronto, Ont.) · 2016Article
- CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.Journal of molecular neuroscience : MN · 2015Article
- Opioids, Neutral Endopeptidase, its Inhibitors and Cancer: Is There a Relationship among them?Archivum immunologiae et therapiae experimentalis · 2015Review
- Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and GastrininAPCMin/+ intestinal polyposis model.Neoplasia (New York, N.Y.) · 2014Article
- MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Role of gastrin-peptides in Barrett's and colorectal carcinogenesis.World journal of gastroenterology · 2012Review
- Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes.Molecular cancer research : MCR · 2012Article
- Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis.American journal of physiology. Gastrointestinal and liver physiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study investigates the effects of gastrin-17 on human colon cancer HT-29 cells to examine whether gastrin receptor (CCK-2), cyclooxygenase (COX-1, COX-2) isoforms and prostaglandin receptor pathways interact to control cell growth. Reverse transcription (RT)-polymerase chain reaction (PCR) analysis demonstrated that HT-29 cells are endowed with the naive expression of CCK-2 receptor (short splice variant), COX-1, COX-2 and prostaglandin EP(4) receptor, but not gastrin. Gastrin-17 significantly promoted cell growth and DNA synthesis. Both these stimulating effects were abolished by L-365,260 or GV150013 (CCK-2 receptor antagonists), but were unaffected by SC-560 (COX-1 inhibitor). L-745,337 (COX-2 inhibitor) or AH-23848B (EP(4) receptor antagonist) partly reversed gastrin-17-induced cell growth, while they fully antagonized the enhancing action on DNA synthesis. HT-29 cells responded to gastrin-17 with a significant increase in prostaglandin E(2) release. This enhancing effect was completely counteracted by L-365,260, GV150013 or L-745,337, while it was insensitive to cell incubation with SC-560. Exposure of HT-29 cells to gastrin-17 was followed by an increased phosphorylation of both extracellular regulated kinases (ERK-1/ERK-2) and Akt. Moreover, gastrin-17 enhanced the transcriptional activity of COX-2 gene promoter and stimulated COX-2 expression. These latter effects were antagonized by L-365,260 or GV150013, and could be blocked also by PD98059 (inhibitor of ERK-1/ERK-2 phosphorylation) or wortmannin (inhibitor of phosphatidylinositol 3-kinase). Analogously, gastrin-17-induced prostaglandin E(2) release was prevented by PD98059 or wortmannin. The present results suggest that (a) in human colon cancer cells endowed with CCK-2 receptors, gastrin-17 is able to enhance the transcriptional activity of COX-2 gene through the activation of ERK-1/ERK-2- and phosphatidylinositol 3-kinase/Akt-dependent pathways; (b) these stimulant actions lead to downstream increments of COX-2 expression, followed by prostaglandin E(2) production and EP(4) receptor activation; (c) the recruitment of COX-2/prostaglandin pathways contributes to the growth-promoting actions exerted by gastrin-17.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.